However, there was a clinically significant association between CCND1 AA genotype and poor survival outcome compared to AG and GG genotypes in contrast to Costea et al., (2006) who studied 205 children of French-Canadian origin with ALL and follow them up for 60 months, the analysis of the impact of CCND1 showed that the individuals with AA variant had a remarkably lower probability of 5-year post-treatment EFS compared to those with AG and GG genotypes (37% compared to 88%, P< 0.00005). The gene discussed is CCND1; the disease is acute lymphoblastic leukemia.